The Franco-Austrian pharmaceutical group Valneva published data on Tuesday showing that its vaccine against chikungunya provided protection for three years with a single dose, which caused its stock to rise on the stock market.
• Also read: Valneva vaccine against chikungunya: favorable European opinion
• Also read: US approves first chikungunya vaccine
Valneva reports in a press release “positive data on the persistence of antibodies three years after vaccination with a single dose of its vaccine against chikungunya, Ixchiq”, in all vaccinated age groups.
Thus, this lasting persistence of antibodies is comparable in older adults (over 65 years) and young adults, details the company which was able to establish protection at two years last year.
On the Paris Stock Exchange, Valneva shares gained 4.20% to 1.86 euros (C$2.75) mid-morning.
The Ixchiq vaccine, which stimulates the body’s production of neutralizing antibodies, was launched in the United States in March 2024. Launches in Canada and Europe are underway. The laboratory plans to obtain marketing authorization in Brazil before the end of the year.
Valneva recently submitted applications for authorization to expand the use of its vaccine to adolescents aged 12 to 17.
Chikungunya virus is a viral disease transmitted by Aedes mosquitoes.
It causes fever, severe joint and muscle pain, headache, nausea, fatigue and skin rashes.
